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background:  New oral anticoagulants (NOACs) including direct thrombin inhibitors (DTIs) and Xa inhibitors offer major advantages over 
vitamin K antagonists. Although officially these agents do not require monitoring, bleeding and ischemic events occur raising concerns for 
over or under inhibition during NOAC therapy. However, no standardized test is currently available. We evaluated the utility of new point-of-
care TEG 6S to quantify anticoagulant effects of NOACs.
Methods:  Anticoagulant effect was assessed in healthy volunteers (n=25) on no medications and in patients with non-valvular atrial 
fibrillation on Xa inhibitors (n= 31) and dabigatran (n=14). Blood was collected at various time intervals since the last dosage. Anticoagulant 
activity was measured using TEG 6S after stimulation with Ecarin (REcarin) and Factor XA (RFXa).
results:  Compared to healthy volunteers, patients on Xa inhibitors had higher RFXa (1.2±.2 vs. 4.2 ±1.8, p<0.001) whereas patients on 
DTIs had higher REcarin (1.5±.2 vs. 3.7±1, p<0.001) and RFXa (1.2±.2 vs. 3.5±1.1, p<0.001) levels. Anticoagulant activity of >2.0 min 
accurately identified patients on DTI and Xa inhibitors with 100% sensitivity and specificity (Figure).
Conclusion:  The automated TEG 6S system with its multichannel anticoagulant cartridge is a highly sensitive and specific test to assess 
the anticoagulant effects of NOACs. Further investigations employing anticoagulation monitoring using this assay are warranted.
 
